Retatrutide Sets a New Ceiling: Inside TRIUMPH-1

Eli Lilly’s triple agonist posted the largest weight loss ever seen in a phase 3 obesity trial. The number the whole field had circled is finally on the table.

For two years, retatrutide was the molecule everyone measured against a promise. On May 21, 2026, the promise became a pivotal result. Eli Lilly announced topline data from TRIUMPH-1, the phase 3 obesity trial, and the headline was the biggest the class has produced: 28.3% mean weight loss at the top dose over 80 weeks.

Retatrutide is unusual in what it switches on. Where semaglutide targets one receptor and tirzepatide two, retatrutide activates three — GLP-1, GIP, and glucagon. That third lever is what its developers bet would push results into new territory.

The TRIUMPH-1 numbers

TRIUMPH-1 was a randomized, double-blind, placebo-controlled trial in 2,339 adults with obesity or overweight and at least one weight-related condition, but without type 2 diabetes. Mean baseline weight was 112.7 kg, with an average BMI of 40.

At 80 weeks, mean weight reduction was 19.0% on the 4 mg dose, 25.9% on the 9 mg dose, and 28.3% on the 12 mg dose, compared with roughly 3.9% on placebo. All three doses met the primary and key secondary endpoints. Nearly half of high-dose patients — about 45% — lost at least 30% of their body weight, a threshold that approaches surgical outcomes. In a prespecified extension to 104 weeks, average loss reached about 30.3%, and, tellingly, the curve had not flattened.

Cardiometabolic markers moved with the weight: waist circumference, cholesterol, and blood pressure all improved.

Where 28.3% sits in the field

Cross-trial comparisons come with caveats — retatrutide has never been tested head-to-head against tirzepatide or semaglutide — but the context is clear. Retatrutide’s phase 2 data, published in The New England Journal of Medicine in 2023, already showed loss above 24%. TRIUMPH-1 extends that lead into pivotal territory, edging past tirzepatide and well past first-generation semaglutide.

The consistency is what impresses. A companion trial, TRIUMPH-4, reported 28.7% in patients with obesity and knee osteoarthritis in late 2025. Two very different populations, nearly identical results — a sign the effect reflects the drug’s mechanism rather than a favorable sample.

The cost side of the ledger

Bigger effects bring bigger trade-offs. Retatrutide’s gastrointestinal side effects — nausea, vomiting, diarrhea — run higher than with earlier drugs, and dropout climbs at the top dose. The glucagon component that drives extra fat burning and energy expenditure also sharpens tolerability challenges. For clinicians, the narrow gap between the 9 mg and 12 mg arms suggests many patients may land on a middle dose that balances loss against comfort.

What happens next

TRIUMPH-1 is topline. Detailed results are headed for a major medical meeting and peer-reviewed publication, following the pattern retatrutide set in 2023. Lilly has guided toward a U.S. regulatory filing late in 2026 to early 2027, which puts a realistic approval decision in late 2027 or 2028.

Seven further phase 3 trials span diabetes, sleep apnea, fatty liver disease, and cardiovascular outcomes, part of a program enrolling thousands. Retatrutide is not approved, and a trial readout is not a prescription. What TRIUMPH-1 establishes is the benchmark. Every rival now designs against 28.3%.

Frequently asked questions

Is retatrutide FDA-approved? Not yet. As of mid-2026, retatrutide has strong phase 3 data from TRIUMPH-1 but remains investigational. Eli Lilly has guided toward a U.S. regulatory filing in late 2026 to early 2027, which would put a possible approval decision in late 2027 or 2028.

How does retatrutide compare to tirzepatide (Zepbound)? The two have never been tested head-to-head, so any comparison is indirect. In their respective trials, retatrutide’s top dose produced roughly 28% weight loss at 80 weeks, edging past tirzepatide’s figures — likely because retatrutide adds a third target, glucagon, on top of GLP-1 and GIP.

Why does retatrutide cause more side effects? The glucagon component that drives extra fat-burning also appears to sharpen the class-typical gastrointestinal effects — nausea, vomiting, diarrhea — and raises dropout at the highest dose. Many patients may settle on a middle dose that balances results against comfort.

Sources

1. Eli Lilly and Company — “Lilly’s triple agonist retatrutide delivered powerful weight loss in pivotal phase 3 obesity trial.” Press release via PR Newswire, May 21, 2026. ClinicalTrials.gov NCT05929066.
2. AJMC — “Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial,” May 2026.
3. HCPLive — “Retatrutide Meets Weight Loss Endpoints in Phase 3 Obesity Trial,” May 2026 (per-dose results and baseline characteristics).
4. Jastreboff, A.M., et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” New England Journal of Medicine, 2023;389:514–526.
5. Eli Lilly and Company — TRIUMPH-4 phase 3 topline (obesity with knee osteoarthritis), December 2025.